IOL CHEMICALS AND PHARMACEUTICALS
|
IOL CHEMICALS AND PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.69 | 3.44 | 22.90 | 23.70 | 28.56 |
| CEPS(Rs) | 7.42 | 5.90 | 6.72 | 6.31 | 7.19 |
| DPS(Rs) | 0.20 | 0.80 | 5.00 | 4.00 | 4.00 |
| Book NAV/Share(Rs) | 61.27 | 57.49 | 274.49 | 256.81 | 237.15 |
| Tax Rate(%) | 25.34 | 26.74 | 26.00 | 26.24 | 25.43 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.60 | 9.73 | 10.81 | 10.18 | 11.83 |
| EBIT Margin(%) | 8.58 | 7.35 | 9.27 | 9.25 | 10.67 |
| Pre Tax Margin(%) | 7.95 | 6.64 | 8.52 | 8.51 | 10.30 |
| PAT Margin (%) | 5.94 | 4.86 | 6.30 | 6.28 | 7.68 |
| Cash Profit Margin (%) | 9.39 | 8.32 | 9.25 | 8.36 | 9.66 |
| Performance Ratios | |||||
| ROA(%) | 5.46 | 4.31 | 6.18 | 6.80 | 8.28 |
| ROE(%) | 7.90 | 6.13 | 8.62 | 9.60 | 12.04 |
| ROCE(%) | 10.65 | 8.86 | 12.24 | 13.57 | 16.25 |
| Asset Turnover(x) | 0.92 | 0.89 | 0.98 | 1.08 | 1.08 |
| Sales/Fixed Asset(x) | 1.46 | 1.50 | 1.91 | 2.52 | 2.87 |
| Working Capital/Sales(x) | 4.31 | 3.84 | 3.81 | 4.78 | 3.85 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.68 | 0.67 | 0.52 | 0.40 | 0.35 |
| Receivable days | 87.89 | 86.45 | 83.56 | 80.26 | 78.51 |
| Inventory Days | 57.58 | 68.94 | 64.21 | 60.53 | 68.50 |
| Payable days | 111.69 | 117.58 | 102.34 | 85.35 | 95.12 |
| Valuation Parameters | |||||
| PER(x) | 15.52 | 17.78 | 3.16 | 11.94 | 12.39 |
| PCE(x) | 9.80 | 10.38 | 10.75 | 8.96 | 9.85 |
| Price/Book(x) | 1.19 | 1.06 | 1.32 | 1.10 | 1.49 |
| Yield(%) | 0.27 | 1.31 | 1.38 | 1.41 | 1.13 |
| EV/Net Sales(x) | 0.89 | 0.82 | 0.94 | 0.78 | 0.91 |
| EV/Core EBITDA(x) | 7.13 | 7.59 | 7.72 | 6.84 | 6.82 |
| EV/EBIT(x) | 10.40 | 11.17 | 10.18 | 8.38 | 8.49 |
| EV/CE(x) | 1.07 | 0.94 | 1.22 | 1.08 | 1.38 |
| M Cap / Sales | 0.92 | 0.86 | 1.00 | 0.75 | 0.95 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.54 | -2.51 | -3.80 | 1.52 | - |
| Core EBITDA Growth(%) | 29.21 | -13.79 | 3.73 | -13.45 | - |
| EBIT Growth(%) | 30.24 | -22.77 | -3.59 | -12.02 | - |
| PAT Growth(%) | 36.18 | -24.82 | -3.39 | -17.02 | - |
| EPS Growth(%) | 36.18 | -84.96 | -3.38 | -17.02 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.07 | 0.02 | 0.05 | 0.03 |
| Current Ratio(x) | 1.73 | 1.85 | 1.94 | 1.92 | 1.99 |
| Quick Ratio(x) | 1.23 | 1.28 | 1.23 | 1.28 | 1.27 |
| Interest Cover(x) | 13.67 | 10.35 | 12.28 | 12.45 | 28.12 |
| Total Debt/Mcap(x) | 0.06 | 0.07 | 0.02 | 0.05 | 0.02 |
Compare Financial Ratios of peers of IOL CHEMICALS AND PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| IOL CHEMICALS AND PHARMACEUTICALS | ₹4,608.0 Cr | -5.5% | 4% | 76.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,394.0 Cr | -2.3% | -3.3% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹226,312.0 Cr | 0.3% | 16.3% | 44.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹190,678.0 Cr | 2.8% | -0.5% | 37.1% | Stock Analytics | |
| CIPLA | ₹114,392.0 Cr | -3.1% | -1.2% | -5.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,740.5 Cr | -2.9% | -3% | -3.3% | Stock Analytics | |
IOL CHEMICALS AND PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| IOL CHEMICALS AND PHARMACEUTICALS | -5.5% |
4% |
76.9% |
| SENSEX | -1.4% |
-1% |
-4.6% |
You may also like the below Video Courses
